Gynecologic Cancer Clinical Trials
When appropriate, we also offer our patients the option to participate in clinical trials to try a promising new medical drug or other treatment. New treatments through clinical trials are expected to be at least as effective as — or possibly more effective than — current treatments.
Clinical trials test new treatment options only after they have first been researched in the laboratory, where they are carefully studied in the test tube and in laboratory animals. Only the treatments most likely to work are further evaluated in humans during clinical trials. For any new drug or treatment to receive approval by the U.S. Food and Drug Administration (FDA) and become available to the public, it must pass through three phases of clinical trials to show that it is safe and effective in treating the disease. If the FDA approves the drug, it will continue to be monitored for safety and effectiveness in what is known as a Phase 4 study.
Clinical Trials match your criteria
-
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab (ARTISTRY-7)
A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
-
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T-Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants with Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors.
-
Screening Study to Determine HLA Type, HLA Loss of Heterozygosity Status and Tumor Antigen Expression in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumors
Screening Study to Determine HLA Type, HLA Loss of Heterozygosity Status and Tumor Antigen Expression in Participants with Locally Advanced (Unresectable) or Metastatic Solid Tumors.
-
Phase II study using LN-145 for Persistent Cervical Cancer
A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma
Navigate Your Health
Find a Cancer Physician
Find a Cancer Physician
Meet our doctors who specialize in the full range of cancer care. Our team of experts has experience in a variety of specialty areas. Together, we provide comprehensive evaluation, diagnosis and treatment options.
Learn MorePatient Portal
Patient Portal
If you are a patient at Orlando Health Cancer Institute, our free online patient portal provides an easy and secure way to manage your health information. Reach us from any location at a time that’s convenient for you.
Learn MoreVirtual Visit
Virtual Visit
Need to talk with a doctor, but don’t want to leave your home? Try our virtual visit (telehealth) option to connect with a physician from your phone, tablet or computer.
Learn More